AR106588A1 - Derivados de indolin-2-ona para el tratamiento de enfermedades del snc - Google Patents

Derivados de indolin-2-ona para el tratamiento de enfermedades del snc

Info

Publication number
AR106588A1
AR106588A1 ARP160103363A ARP160103363A AR106588A1 AR 106588 A1 AR106588 A1 AR 106588A1 AR P160103363 A ARP160103363 A AR P160103363A AR P160103363 A ARP160103363 A AR P160103363A AR 106588 A1 AR106588 A1 AR 106588A1
Authority
AR
Argentina
Prior art keywords
disease
group
disorders
lower alkyl
treatment
Prior art date
Application number
ARP160103363A
Other languages
English (en)
Inventor
Halm Remy
Stoll Theodor
Plancher Jean
Marc Kolczewski Sabine
Gaufreteau Delphine
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR106588A1 publication Critical patent/AR106588A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Derivados de indolin-2-ona. Los compuestos pueden usarse en el tratamiento de enfermedades del SNC relacionadas con síntomas positivos (psicosis) y negativos de la esquizofrenia, abuso de sustancias, alcohol y drogadicción, trastornos obsesivo-compulsivos, deterioro cognitivo, trastornos bipolares, trastornos del estado de ánimo, depresión mayor, depresión resistente al tratamiento, trastornos de ansiedad, enfermedad de Alzheimer, autismo, enfermedad de Parkinson, dolor crónico, trastorno límite de la personalidad, enfermedad neurodegenerativa, alteraciones del sueño, síndrome de la fatiga crónica, rigidez, enfermedad inflamatoria, asma, enfermedad de Huntington, ADHD, esclerosis lateral amiotrófica, efectos en la artritis, enfermedad autoinmunitaria, enfermedades víricas y fúngicas, enfermedades cardiovasculares, enfermedades oftalmológicas e inflamatorias de la retina y problemas de equilibrio, epilepsia y trastornos del neurodesarrollo con epilepsia comórbida. Reivindicación 1: Un compuesto de fórmula (1) en donde A es fenilo o un grupo heteroarilo de cinco o seis miembros, que contiene uno o dos átomos de N, seleccionados entre los restos del grupo de fórmulas (2); o el grupo amida -C(O)-NR¹R² puede formar junto con dos átomos de carbono colindantes a partir del grupo A un anillo condensado adicional, seleccionados entre los restos del grupo de fórmulas (3); R¹ / R² son independientemente el uno del otro, hidrógeno, alquilo inferior, alquilo inferior sustituido con halógeno, alquilo inferior sustituido con hidroxi, -(CH₂)₂-alcoxi inferior, oxetanilo, cicloalquilo, CH₂-cicloalquilo, anillos cicloalquilo que están opcionalmente sustituidos con halógeno; o R¹ y R² pueden formar junto con el átomo de N al que están unidos el grupo de fórmula (4); R³ es hidrógeno o alquilo inferior; así como sales farmacéuticamente aceptables de los mismos, con una mezcla racémica, o con su enantiómero correspondiente y/o isómero óptico y/o estereoisómero del mismo.
ARP160103363A 2015-11-06 2016-11-04 Derivados de indolin-2-ona para el tratamiento de enfermedades del snc AR106588A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15193342 2015-11-06

Publications (1)

Publication Number Publication Date
AR106588A1 true AR106588A1 (es) 2018-01-31

Family

ID=54476820

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103363A AR106588A1 (es) 2015-11-06 2016-11-04 Derivados de indolin-2-ona para el tratamiento de enfermedades del snc

Country Status (34)

Country Link
US (2) US10710985B2 (es)
EP (1) EP3371168B1 (es)
JP (1) JP6857662B2 (es)
KR (1) KR20180080305A (es)
CN (1) CN108349944B (es)
AR (1) AR106588A1 (es)
AU (1) AU2016348493B2 (es)
BR (1) BR112018008056A2 (es)
CA (1) CA3002489C (es)
CL (1) CL2018001085A1 (es)
CO (1) CO2018005718A2 (es)
CR (1) CR20180255A (es)
DK (1) DK3371168T3 (es)
ES (1) ES2808920T3 (es)
HK (1) HK1257170A1 (es)
HR (1) HRP20201158T1 (es)
HU (1) HUE050083T2 (es)
IL (1) IL258656A (es)
LT (1) LT3371168T (es)
MA (1) MA43159B1 (es)
MX (1) MX2018005121A (es)
MY (1) MY197370A (es)
PE (1) PE20181885A1 (es)
PH (1) PH12018500978A1 (es)
PL (1) PL3371168T3 (es)
PT (1) PT3371168T (es)
RS (1) RS60504B1 (es)
RU (1) RU2727179C2 (es)
SG (1) SG11201803796SA (es)
SI (1) SI3371168T1 (es)
TW (1) TWI631117B (es)
UA (1) UA122589C2 (es)
WO (1) WO2017076852A1 (es)
ZA (1) ZA201802411B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017076842A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
PE20181885A1 (es) 2015-11-06 2018-12-07 Hoffmann La Roche Derivados de indolin-2-ona
WO2017076931A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
EP3371170B1 (en) 2015-11-06 2019-07-31 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives useful in the treatment of cns diseases
EP4038192A4 (en) 2019-10-01 2023-11-01 Empyrean Neuroscience, Inc. GENETIC MANIPULATION OF MUSHROOMS TO MODULATE TRYPTAMINE EXPRESSION
CN115298163A (zh) * 2020-04-29 2022-11-04 巴斯夫欧洲公司 通过钯催化的羰基化反应制备芳族羧酰胺

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW251284B (es) 1992-11-02 1995-07-11 Pfizer
DE4427648A1 (de) 1994-08-04 1996-02-08 Basf Ag N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
ES2199447T3 (es) 1997-06-16 2004-02-16 Janssen Pharmaceutica N.V. Utilizacion de un analogo de draflazina para tratamiento del dolor.
WO2000040581A1 (en) 1999-01-07 2000-07-13 American Home Products Corporation 3,4-dihydro-2h-benzo[1,4]oxazine derivatives
IT1318403B1 (it) 2000-03-17 2003-08-25 Cooperativa Ct Ricerche Poly T Esteri polisaccaridici di n-derivati di acido glutammico.
AU2001249397A1 (en) 2000-03-24 2001-10-08 Cor Therapeutics, Inc. Oxindole inhibitors of factor xa
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
EP1634594A1 (en) 2000-06-29 2006-03-15 NeuroSearch A/S Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators
US6524302B2 (en) 2001-04-26 2003-02-25 Scimed Life Systems, Inc. Multi-lumen catheter
US7582616B2 (en) 2002-12-31 2009-09-01 Quesrema Enterprises Llc Nucleoside transport inhibitors
NZ551543A (en) 2004-05-11 2009-12-24 Egis Gyogyszergyar Nyrt Pyridine derivatives of alkyl oxindoles as 5-HT7 receptor active agents
DE602004009166T2 (de) 2004-06-29 2008-08-21 Grünenthal GmbH Neue Analoga von Nitrobenzylthioinosin
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
CA2615007A1 (en) 2005-07-13 2007-01-18 F. Hoffmann-La Roche Ag Benzimidazole derivatives as 5-ht6,5-ht24
US20070265270A1 (en) * 2006-02-21 2007-11-15 Hitchcock Stephen A Cinnoline derivatives as phosphodiesterase 10 inhibitors
JP2009529053A (ja) 2006-03-07 2009-08-13 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の処置のための組成物および方法
BRPI0712938A2 (pt) * 2006-06-26 2013-03-26 Helicon Therapeutics Inc mÉtodo para modular excrescÊncia de neurito pelo uso de um antagonista de receptor de galanina-3
US7952109B2 (en) 2006-07-10 2011-05-31 Alcatel-Lucent Usa Inc. Light-emitting crystal structures
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
PE20081401A1 (es) * 2006-12-28 2008-10-24 Hoffmann La Roche Derivados de indol como antagonistas de receptores vasopresina
PL2114921T3 (pl) 2006-12-30 2013-05-31 Abbott Gmbh & Co Kg Podstawiona pochodna oksindolu i jej zastosowanie jako liganda receptora wazopresyny
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
EP2180916B1 (en) 2007-07-30 2014-10-01 University Of Rochester Adenosine as a therapeutic tool to improve the efficacy of deep brain stimulation
JO3126B1 (ar) 2007-11-14 2017-09-20 Janssen Pharmaceutica Nv مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1
US20100266569A1 (en) 2007-11-15 2010-10-21 Mark Zylka Prostatic acid phosphatase for the treatment of pain
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US9090610B2 (en) * 2011-04-21 2015-07-28 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
EP2838538B1 (en) * 2012-04-20 2017-03-15 Annji Pharmaceutical Co., Ltd. Cyclopropanecarboxylate esters of purine analogues
JP6116693B2 (ja) * 2012-09-13 2017-04-19 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cns障害の処置のための2−オキソ−2,3−ジヒドロ−インドール
MX370661B (es) 2013-06-19 2019-12-19 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona.
MY186124A (en) 2014-06-26 2021-06-23 Hoffmann La Roche Indolin-2-one or pyrrolo-pyridin-2-one derivatives
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
WO2017079765A1 (en) 2015-11-06 2017-05-11 Samumed, Llc Treatment of osteoarthritis
WO2017079641A1 (en) 2015-11-06 2017-05-11 Neurocrine Biosciences, Inc. N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
WO2017076842A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
EP3371170B1 (en) 2015-11-06 2019-07-31 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives useful in the treatment of cns diseases
PE20181885A1 (es) 2015-11-06 2018-12-07 Hoffmann La Roche Derivados de indolin-2-ona
WO2017076931A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders

Also Published As

Publication number Publication date
ZA201802411B (en) 2019-01-30
CO2018005718A2 (es) 2018-06-12
JP2018536703A (ja) 2018-12-13
RU2018120703A3 (es) 2020-01-31
DK3371168T3 (da) 2020-08-03
CL2018001085A1 (es) 2018-08-24
HRP20201158T1 (hr) 2020-11-13
MA43159B1 (fr) 2020-08-31
PE20181885A1 (es) 2018-12-07
SG11201803796SA (en) 2018-06-28
TW201726654A (zh) 2017-08-01
CN108349944A (zh) 2018-07-31
CR20180255A (es) 2018-06-22
EP3371168B1 (en) 2020-05-27
RS60504B1 (sr) 2020-08-31
US11066393B2 (en) 2021-07-20
RU2727179C2 (ru) 2020-07-21
PH12018500978A1 (en) 2019-01-28
MY197370A (en) 2023-06-14
CN108349944B (zh) 2021-03-30
ES2808920T3 (es) 2021-03-02
US20200299278A1 (en) 2020-09-24
EP3371168A1 (en) 2018-09-12
AU2016348493A1 (en) 2018-04-26
CA3002489A1 (en) 2017-05-11
HUE050083T2 (hu) 2020-11-30
BR112018008056A2 (pt) 2018-10-23
AU2016348493B2 (en) 2021-02-25
PL3371168T3 (pl) 2020-11-02
MX2018005121A (es) 2018-06-06
US20180251449A1 (en) 2018-09-06
KR20180080305A (ko) 2018-07-11
US10710985B2 (en) 2020-07-14
HK1257170A1 (zh) 2019-10-18
SI3371168T1 (sl) 2020-08-31
RU2018120703A (ru) 2019-12-06
JP6857662B2 (ja) 2021-04-14
IL258656A (en) 2018-06-28
LT3371168T (lt) 2020-10-12
UA122589C2 (uk) 2020-12-10
PT3371168T (pt) 2020-07-17
TWI631117B (zh) 2018-08-01
CA3002489C (en) 2023-11-07
WO2017076852A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
AR106588A1 (es) Derivados de indolin-2-ona para el tratamiento de enfermedades del snc
PH12016502231B1 (en) Indolin-2-one or pyrrolo-pyridin-2-one derivatives
AR096640A1 (es) Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona
AR106590A1 (es) Derivados de indolin-2-ona
AR106589A1 (es) Derivados de indolin-2-ona
CR20180022A (es) Derivados etinilo.
MX2016008842A (es) Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos.
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
AR106591A1 (es) Derivados de indolin-2-ona
EA201692488A1 (ru) Пептиды, выполняющие роль агонистов окситоцина
MX2016000895A (es) Derivados de 1,7-naftiridina.
AR093576A1 (es) Derivados heterociclicos sustituidos
PH12016501100B1 (en) Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators
MX2015015052A (es) Derivados de isoquinolina que estimulan la neurogenesis.
AR093519A1 (es) 1,6-naftiridinas sustituidas
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
AR100210A1 (es) Derivados de piridina con afinidad a taar
EA201691788A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
PH12016500605A1 (en) Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders
EA201692404A1 (ru) Пептиды, выполняющие роль агонистов окситоцина
AR100532A1 (es) Derivados de indolín-2-ona y 1,3-dihidro-pirrolo[3,2-c]piridín-2-ona
BR112015008200A2 (pt) derivados de imidazopiridina
MX363461B (es) Derivados de benzisoxazol como moduladores de la neurogénesis y el uso de los mismos en el tratamiento de enfermedades neurológicas y trastornos neuropsiquiátricos.
MX2016001528A (es) Derivados de indol-carboxamida.
TH165816B (th) ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท